Organon & Co. (NYSE:OGN) Shares Purchased by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. raised its stake in shares of Organon & Co. (NYSE:OGN) by 39.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 115,213 shares of the company’s stock after buying an additional 32,413 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Organon & Co. were worth $1,661,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of OGN. Fairfield Bush & CO. grew its holdings in Organon & Co. by 3.0% during the 1st quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock valued at $569,000 after buying an additional 481 shares during the last quarter. Natixis Advisors L.P. grew its holdings in Organon & Co. by 52.5% during the 1st quarter. Natixis Advisors L.P. now owns 50,428 shares of the company’s stock valued at $1,761,000 after buying an additional 17,370 shares during the last quarter. MetLife Investment Management LLC grew its holdings in Organon & Co. by 23.2% during the 1st quarter. MetLife Investment Management LLC now owns 68,987 shares of the company’s stock valued at $2,410,000 after buying an additional 12,969 shares during the last quarter. Panagora Asset Management Inc. grew its holdings in Organon & Co. by 95.6% during the 1st quarter. Panagora Asset Management Inc. now owns 39,595 shares of the company’s stock valued at $1,383,000 after buying an additional 19,352 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Organon & Co. by 6.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,926 shares of the company’s stock valued at $1,185,000 after buying an additional 2,101 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Up 0.6 %

Shares of Organon & Co. stock opened at $18.27 on Friday. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79. The firm has a market cap of $4.67 billion, a PE ratio of 4.57, a P/E/G ratio of 0.86 and a beta of 0.83. The business’s fifty day moving average is $17.87 and its two-hundred day moving average is $15.60.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. Equities research analysts anticipate that Organon & Co. will post 4.08 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 6.13%. The ex-dividend date of this dividend was Friday, February 23rd. Organon & Co.’s dividend payout ratio (DPR) is currently 28.00%.

Analyst Ratings Changes

Separately, The Goldman Sachs Group increased their price target on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 20th.

Insider Buying and Selling

In other news, insider Kirke Weaver bought 2,720 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average cost of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now owns 15,181 shares of the company’s stock, valued at approximately $278,723.16. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.17% of the company’s stock.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.